Seres therapeutics presents data supporting its microbiome pipeline at idweek 2021, including data from ser-109 phase 3 ecospor iii study in recurrent c. difficile infection

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today announced data from its phase 3 ecospor iii study evaluating ser-109, an investigational oral microbiome therapy for recurrent c. difficile infection (rcdi), will be presented at the idweek 2021 virtual conference (sept. 29-oct. 3). the company will be presenting seven posters and oral presentations related to ser-109 and c. difficile, including a late-breaker, as well as
MCRB Ratings Summary
MCRB Quant Ranking